Author

Karen Midthun

Observed name: KAREN MIDTHUN

Observed institutions: Ben-Gurion University of the Negev, Centers for Disease Control and Prevention, National Institutes of Health, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Center for Drug Evaluation and Research, Johns Hopkins University, National Center for Immunization and Respiratory Diseases, Hiroshima Bunka Gakuen University, Soroka Medical Center, Palo Alto Veterans Institute for Research, World Health Organization, National Institute of Allergy and Infectious Diseases, Massachusetts Institute of Technology, Stanford University

OpenAlex ID: A5104669279

Developing the Nation's Biosimilars Program

2011 · Steven Kozlowski, Janet Woodcock, et al. · New England Journal of Medicine · 194

The Safety and Immunogenicity of a Human Immunodeficiency Virus Type 1 (HIV-1) Recombinant gp160 Candidate Vaccine in Humans

1991 · Raphael Dolin, Barney S. Graham, et al. · Annals of Internal Medicine · 167

Comparison of the amino acid sequences of the major neutralization protein of four human rotavirus serotypes

1987 · Kim Y. Green, Karen Midthun, et al. · Virology · 133

The US Food and Drug Administration's Sentinel Initiative: Expanding the horizons of medical product safety

2012 · Melissa A. Robb, Judith A. Racoosin, et al. · Pharmacoepidemiology and Drug Safety · 116

PDF

The Food and Drug Administration's Post‐Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise

2012 · Michael Nguyen, Robert Ball, et al. · Pharmacoepidemiology and Drug Safety · 105

PDF

Safety and immunogenicity of live attenuated human–bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants1This study was presented, in part, in a poster session at the Fifth Rotavirus Vaccine Workshop held on October 16–17, 1995, at the Centers for Disease Control and Prevention in Atlanta, GA. Informed consent was obtained from adult volunteers and the parents or guardians of pediatric participants. The guidelines for human experimentation of the U.S. Department of Health and Human Services and those of Johns Hopkins University and Vanderbilt University were followed in the conduct of these clinical studies.1

1999 · Mary Lou Clements-Mann, Mamodikoe K Makhene, et al. · Vaccine · 76

Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS

2009 · Brigitte Autran, Edwin J Asturias, et al. · Expert Review of Vaccines · 66

Evaluating the Safety of New Vaccines: Summary of a Workshop

2005 · Susan S. Ellenberg, Mary A. Foulkes, et al. · American Journal of Public Health · 56

1985 · Jorge Flores, Irene Perez‐Schael, et al. · Journal of Medical Virology · 54

Strategies for the Development of a Rotavirus Vaccine Against Infantile Diarrhea with an Update on Clinical Trials of Rotavirus Vaccines

1989 · Albert Z. Kapikian, Jorge Flores, et al. · Advances in experimental medicine and biology · 43

An Update on the “Jennerian” and Modified “Jennerian” Approach to Vaccination of Infants and Young Children Against Rotavirus Diarrhea

1992 · Albert Z. Kapikian, Timo Vesikari, et al. · Advances in experimental medicine and biology · 31

Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis A

1992 · Edward F. Ellerbeck, John A. Lewis, et al. · Vaccine · 30

Prospects for Development of a Rotavirus Vaccine Against Rotavirus Diarrhea in Infants and Young Children

1989 · Albert Z. Kapikian, Jorge Flores, et al. · Clinical Infectious Diseases · 29

Regulation and testing of vaccines

2008 · Norman W. Baylor, Karen Midthun · Elsevier eBooks · 26

Safety and immunogenicity of oral tetravalent human-rhesus reassortant rotavirus vaccine in neonates

1992 · RON DAGAN, IMAD KASSIS, et al. · The Pediatric Infectious Disease Journal · 26

Take of rhesus‐human reassortant tetravalent rotavirus vaccine in breast‐fed infants

1993 · Mehmet Ceyhan, Güler Kanra, et al. · Acta Paediatrica · 25

Reactogenicity and antigenicity of rhesus rotavirus vaccine (MMU-18006) in newborn infants in Venezuela

1988 · JORGE FLORES, GEORGETTE DAOUD, et al. · The Pediatric Infectious Disease Journal · 20

Control of Viral Infections and Diseases

1996 · Karen L. Goldenthal, Karen Midthun, et al. · 18

Rationale for the Development of a Rotavirus Vaccine for Infants and Young Children

1989 · Albert Z. Kapikian, Jorge Flores, et al. · Progress in vaccinology · 17

Recent Advances in Development of a Rotavirus Vaccine for Prevention of Severe Diarrheal Illness of Infants and Young Children

1991 · Albert Z. Kapikian, Jorge Flores, et al. · Advances in experimental medicine and biology · 14

Testing and Licensure of Combination Vaccines for the Prevention of Infectious Diseases

1999 · Lydia A. Falk, Karen Midthun, et al. · Humana Press eBooks · 9

FDA senior management perspectives

2005 · Janet Woodcock, Robert Temple, et al. · Clinical Trials · 4

Getting the Science Right and Doing the Right Science in Vaccine Safety

2004 · Roger Bernier, Karen Midthun · American Journal of Public Health · 4

Developing Safe Vaccines

2004 · Norman Baylor, Karen Midthun, et al. · Informa Healthcare eBooks · 3

Nonsense suppressor mutants of bacteriophage T5

1982 · Anthony Macaluso, Karen Midthun, et al. · Virology · 1

Works count: 30

Citation count: 1,267

H-index: 18

I10-index: 20